Bipolar Animals: A Comprehensive Look at Mood Research

No animal has been diagnosed with bipolar disorder in the way a psychiatrist would diagnose a human, but researchers have spent decades engineering states in mice, rats, zebrafish, and primates that mimic the extreme highs and lows of the condition. Most of these animal models capture only one pole at a time, either mania-like hyperactivity or depression-like withdrawal, and only a handful attempt to reproduce the cycling between the two that defines the human illness.¹ The gap between a mouse swimming in a beaker and a person navigating a manic episode is enormous, yet these models remain some of the best tools science has for understanding mood at a biological level.

Why Animal Models of Bipolar Disorder Are So Difficult to Build

Bipolar disorder in humans involves subjective experiences: grandiosity, racing thoughts, crushing hopelessness, euphoria. You cannot ask a mouse whether it feels euphoric. What researchers can do is look for behaviors that map loosely onto human symptoms and then test whether those behaviors respond to the same drugs that help people. A mouse that suddenly runs laps around its cage, barely sleeps, and takes unusual risks looks something like mania. A rat that stops trying to escape a stressful situation looks something like depression. Whether the animals actually “feel” anything resembling the human experience is an open philosophical question that most researchers sidestep by talking about “mania-like” or “depression-like” behavior instead.

The real challenge is the cycling. Human bipolar disorder is defined not just by extreme states but by the switch between them, sometimes over weeks, sometimes over months. Recreating that oscillation in an animal on a laboratory timeline has proven stubbornly hard. Most models induce one state and study it in isolation. A few genetic approaches in mice have shown potential for investigating the mechanisms behind behavioral switching, but these remain the exception rather than the rule.²

How Researchers Measure “Mood” in a Rodent

If you cannot interview an animal, you need standardized behavioral tests, and the field has developed a whole toolkit. The most widely used assay for depression-like behavior is the forced swim test. A rodent is placed in a cylinder of water with no escape route. It swims vigorously at first, then eventually stops and floats. The time it takes to give up is treated as a proxy for behavioral despair: animals that stop swimming sooner are considered to show a more depression-like phenotype.³ The test is also used to screen drugs; antidepressants tend to keep animals swimming longer.⁴

On the mania side, the open field test is a workhorse. A mouse is placed in a simple arena and its movement is tracked by video software. Researchers measure total distance traveled, how often the animal ventures into the exposed center of the arena (a sign of reduced anxiety or increased risk-taking), and whether its movement patterns become repetitive or stereotyped. An animal in a drug-induced manic state will often cover dramatically more ground, spend more time in the center, and show movement patterns that look disorganized compared to a control animal.⁵

More recently, researchers have tried combining tests. One group developed a hybrid assay for female mice that merges the forced swim test with a light-dark preference setup, allowing them to evaluate anxiety-like and depression-like behavior simultaneously in the same session. The anxiety component was sensitive to stress hormones, and the depression component responded to clinical antidepressants like fluoxetine and paroxetine.⁶ These hybrid approaches reflect a growing recognition that mood disorders rarely present as a single clean symptom.

Drugs That Flip the Switch

The oldest and most straightforward way to create a mania-like state in an animal is to give it a drug that floods the brain with dopamine. Amphetamine has been used for decades in this role. Inject a rat with a high dose, and you get hyperactivity, reduced sleep, and stereotyped movements that look convincingly manic. Critically, lithium, the gold-standard mood stabilizer in humans, tends to calm these animals down, which gives the model what researchers call “predictive validity”: if a model responds to human treatments, it is probably tapping into something real.

A different pharmacological approach uses ouabain, a compound that disrupts sodium-potassium pump function in the brain. When injected into the brain ventricles of rats, ouabain produces a pattern of initial hyperactivity followed by a depressive phase, making it one of the few drug models that captures something resembling cycling. The depressive phase comes with measurable neuroinflammation, and lithium reverses both the behavioral and inflammatory changes.⁷

Yet another method uses the GABA-blocking compound pentylenetetrazol at low doses in zebrafish larvae, producing a range of behavioral changes that resemble bipolar symptoms. Established mood stabilizers like carbamazepine and valproic acid reduce these changes, which helps validate the model as a screening tool for potential new drugs.⁸

Genetic Models and the Clock Gene

Pharmacological models are useful but blunt. You are essentially poisoning an animal into a mood state and hoping the biology overlaps with what happens naturally in humans. Genetic models aim to be more precise by altering specific genes linked to bipolar disorder in human studies.

One of the most studied is the Clock-mutant mouse. The CLOCK gene helps regulate circadian rhythms, and disrupted sleep-wake cycles are a hallmark of bipolar disorder in humans. Mice carrying a mutation in this gene (called ClockΔ19) show a suite of mania-like behaviors: they travel farther in open-field tests, spend more time in the risky open arms of an elevated maze, and show reduced activity in brain areas involved in impulse control.⁹ These mice essentially act as if they are in a permanent manic episode, which makes them useful for studying the neurobiology of that state even if they do not cycle into depression.

Another genetic approach targets the dopamine transporter, the protein that clears dopamine out of the synaptic gap after it has been released. Mice bred with reduced dopamine transporter function (called DAT knockdown mice) show an exploratory profile that matches the quantified behavior of manic bipolar patients tested in the same cross-species apparatus, known as the Behavioral Pattern Monitor.⁵ The fact that researchers can use the same testing setup in both humans and mice, then compare the movement signatures directly, is a meaningful step toward bridging the species gap.

Beyond these, scientists have created models by altering genes involved in a variety of pathways implicated in bipolar disorder, including those regulating mitochondrial DNA repair, glutamate signaling, and the enzyme GSK-3β, which is a known target of lithium.² Each model illuminates a different piece of the puzzle, but none captures the full picture on its own.

Why Zebrafish Are Becoming a Bigger Deal

Mice and rats dominate mood research, but zebrafish are gaining ground fast. They develop externally and are transparent in their larval stage, which means you can watch a brain form in real time. They absorb drugs directly from the water they swim in, making dosing trivially easy. They need far less space than rodents, and they reproduce quickly, allowing researchers to run large-scale screens that would be impractical with mammals.¹⁰

One zebrafish model of bipolar disorder uses a compound called CIP to induce manic-like behavior in adult fish. After a two-week treatment with lithium carbonate, the manic-like locomotion and behavior frequency returned to levels that were not significantly different from healthy controls, validating the model’s relevance for drug testing.¹¹ Molecular profiling of these fish revealed neuroinflammation and synaptic damage mediated by a specific stress-signaling pathway, offering potential new drug targets that would have been much harder to identify in a mammalian system.

The obvious limitation is that a zebrafish brain is vastly simpler than a human or even a mouse brain. No zebrafish will ever model grandiosity or racing thoughts. But for rapidly screening whether a candidate compound affects mood-relevant circuits and inflammation pathways, fish offer a speed and scale that rodent work cannot match.

Inflammation as a Common Thread

One of the more striking findings to come out of animal mood research is how consistently inflammation shows up. In humans, bipolar disorder is associated with elevated inflammatory markers in the blood and brain. Animal models have helped pin down the mechanics. When rats are given amphetamine to induce mania-like behavior, levels of several inflammatory molecules, including IL-6 and TNF-α, spike in the frontal cortex, striatum, and blood. Lithium reverses these increases.¹² The ouabain model tells a similar story: inflammation rises in the frontal cortex and hippocampus alongside depressive-like behavior, and lithium brings both back to baseline.⁷

The gut-brain connection adds another layer. In a mouse model of postpartum depression, changes in gut bacteria composition were enough to drive depression-like and anxiety-like behavior, along with inflammation in the hippocampus. Transplanting gut bacteria from healthy mice into depressed mice reduced both the behavioral symptoms and the brain inflammation. Intriguingly, this rescue failed when researchers artificially overexpressed a key inflammatory protein in the hippocampus, suggesting that the gut-brain benefit runs directly through the inflammatory pathway.¹³ While this model focused on postpartum depression specifically, the inflammation-centered mechanism overlaps heavily with what is seen in bipolar models, reinforcing the idea that neuroinflammation is a shared vulnerability across mood disorders.

What Primate Neuroimaging Adds

Rodents and fish are workhorses for genetic and pharmacological experiments, but when you want to study brain-wide network activity in something that resembles a human brain, primates become essential. In one study, researchers gave ketamine to anesthetized monkeys and then mapped the resulting changes in brain connectivity. They observed a large-scale, persistent reconfiguration of brain networks, with the most prominent drops in connectivity occurring in the orbital prefrontal cortex, the subgenual cingulate, and the nucleus accumbens, all regions heavily implicated in mood regulation in humans.¹⁴ Ketamine has rapid antidepressant effects in humans, and seeing it reshape the same brain regions in primates that light up in human depression imaging studies strengthens the translational link.

A separate study in awake female primates found that ketamine increased connectivity to the dorsolateral prefrontal cortex, a region involved in working memory and executive control, across several cortical and subcortical areas.¹⁵ The fact that anesthetized and awake primates show complementary patterns of network reorganization after the same drug helps researchers build a richer picture of what ketamine actually does to mood-relevant circuits, filling in gaps that human imaging studies cannot easily address because of ethical and practical constraints.

Seasonal Mood Shifts in the Wild

While most animal mood research happens in the lab, there are naturally occurring phenomena that look an awful lot like mood cycling in the wild. Several rodent species show depression-like behavior when exposed to short winter-like day lengths. Siberian hamsters, fat sand rats, and Nile grass rats all display reduced activity and behavioral changes that mirror depressive phenotypes when the lights stay off for longer periods. These changes are accompanied by measurable decreases in hippocampal volume and whole brain volume, paralleling the hippocampal shrinkage seen in depressed humans.¹⁶

One evolutionary hypothesis proposes that the behavioral patterns underlying bipolar disorder may have originally evolved in the northern temperate zone during the Pleistocene ice ages, as adaptations to severe seasonal swings. Hypomania in summer, when food was abundant and risks could pay off, and depressive withdrawal in winter, when energy conservation mattered more, could have been advantageous in that context.¹⁷ This remains a hypothesis, not established fact, but the seasonal mood shifts observed in wild-type rodents are at least consistent with it. Whether these animals experience anything we would recognize as “moods” is unknowable, but the neurobiological machinery is there.

Environmental Enrichment and What It Tells Us About Prevention

If drugs and genes can push animal mood in a negative direction, can environment pull it back? The research on environmental enrichment, giving animals toys, climbing structures, social companions, and novel objects to explore, says yes. A global overview of enrichment studies found that roughly four out of five reported positive effects on the animals studied.¹⁸

The timeline matters, though. In one study, both short-term and long-term environmental enrichment increased home-cage activity and reduced depression-like behavior in the forced swim test. But the two durations did not produce identical effects: short-term enrichment also reduced body weight and had anti-anxiety effects in a separate maze test, while those benefits disappeared with long-term exposure.¹⁹ This suggests that the brain adapts to its environment in complex ways, and that the benefits of enrichment are not simply cumulative. For mood research, the practical implication is that housing conditions profoundly affect baseline behavior, which means a study conducted in a bare cage might produce different results from one conducted in an enriched cage, potentially complicating comparisons across labs.

When the Research Comes Home to Pets

The question of whether companion animals experience mood disorders is separate from whether lab animals can model human ones, but the two fields are starting to talk to each other. Dogs show separation anxiety, compulsive behaviors, and states that veterinary behaviorists describe in mood-adjacent terms. Cats are trickier to read, but they are increasingly being treated with psychoactive medications originally developed for humans.

A retrospective study of 176 cats diagnosed with various behavioral disorders found that a substantial portion showed meaningful improvement on venlafaxine, a drug used to treat depression and anxiety in people. About a fifth of the cats were eventually weaned off the medication without relapsing. Side effects were reported in roughly a third of the cats but were mostly minor and short-lived.⁶ This does not prove cats have bipolar disorder, and the study did not diagnose any cat with that specific condition. But it does show that the same neurochemical systems targeted by human mood medications are active in companion animals and that modulating them changes behavior in predictable directions.

The Evolving Toolkit

Animal mood research has changed significantly over the past two decades. Early models relied heavily on pharmacological induction: give a rat amphetamine, see if lithium calms it down, and call it a day. Modern approaches are more sophisticated. Genetic tools allow researchers to turn individual genes on or off with precision. Circuitry-based techniques let them activate or silence specific brain pathways in real time. Automated testing systems track behavior around the clock, capturing subtleties that a human observer would miss.²⁰

Perhaps the most important conceptual shift has been away from trying to recreate the whole disorder in one animal and toward modeling specific dimensions of it. Rather than asking “does this mouse have bipolar disorder?” researchers increasingly ask “does this mouse show the reward-seeking behavior associated with mania?” or “does this fish show the inflammation pattern associated with depressive episodes?” This dimension-by-dimension approach accepts that no single animal will ever fully model a uniquely human condition, and instead focuses on getting each piece right so the biological mechanisms can be studied in isolation and eventually assembled into a more complete understanding.

The approach is bearing fruit in drug development. Zebrafish screens can identify promising compounds in weeks rather than months. Genetic mouse models have pointed researchers toward specific inflammatory and circadian pathways that are now being explored as targets for new bipolar medications. Primate imaging studies provide a bridge between the molecular detail available in rodents and the brain-network data available in humans. No single species tells the whole story, but together they are steadily narrowing the gap between what we can observe in a lab animal and what a person with bipolar disorder actually experiences.